Search Results

You are looking at 21 - 30 of 72 items for :

  • Refine by Access: All x
Clear All
Full access

Gary H. Lyman

Skipper HE : Kinetics of Mannary Tumor Cell Growth and Implications for Therapy . Cancer 1971 ; 28 : 1479 . 40 Early Breast Cancer Trialists' Collaborative Group . Effects of chemotherapy and hormonal therapy for early breast cancer on

Full access

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shanefelt, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Maria Ho

other factors (eg, age, ethnicity, family history, PSA kinetics) should also inform the decision to perform a biopsy. Several panel members also noted that risk calculators could be used in appropriately selected men. These calculators have been

Full access

Antonio Di Meglio, Nancy U. Lin, Rachel A. Freedman, William T. Barry, Eric P. Winer, and Ines Vaz-Luis

testing. Abbreviation: TM, tumor marker. workup for metastatic disease. 5 Nevertheless, in both, TM testing is given as an option for monitoring mBC. 5 , 10 The kinetics of CEA and CA 15-3 have been retrospectively correlated with treatment

Full access

Dung T. Le and Elizabeth M. Jaffee

-Tricom vaccine, 18 patients who were predicted to have indolent disease using the Halabi prediction nomogram 19 lived a median of more than 37.3 months. This suggests that if the kinetics of tumor growth outpace the kinetics of immune induction, then

Full access

David Y. Oh, Alan P. Venook, and Lawrence Fong

to future investigations of CRC immunotherapy. Clinical Considerations With Immunotherapies The kinetics of clinical responses can be very different with immunotherapies. A common feature of several of the approved immune therapies (in

Full access

Chezi Ganzel, Dan Douer, and Martin S. Tallman

PML/RARα Analysis in a Patient Treated With ATO The kinetics of leukemia cell clearance after the use of ATO is significantly different from that of ATRA-based therapy. Thus, a group from India tried to explore, prospectively, the most informative

Full access

Shailender Bhatia and John A. Thompson

routine use of maintenance dosing of ipilimumab is currently not recommended, although reinduction doses may be considered at disease progression in patients who have clearly benefitted from induction doses of ipilimumab. Response Kinetics and Patterns

Full access

Neelima N. Nallapaneni, Rajesh Mourya, Vijaya Raj Bhatt, Sakshi Malhotra, Apar Kishor Ganti, and Ketki K. Tendulkar

: 1376 – 1385 . 3. Weber JS Kahler KC Hauschild A . Management of immune-related adverse events and kinetics of response with ipilimumab . J Clin Oncol 2012 ; 30 : 2691 – 2697 . 4. Weber JS Dummer R de Pril V . Patterns of onset

Full access

Brandon A. Mahal, Ming-Hui Chen, Andrew A. Renshaw, Marian J. Loffredo, Philip W. Kantoff, and Anthony V. D'Amico

following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database . BJU Int 2010 ; 105 : 28 – 33 . 31. Lee AK D'Amico AV . Utility of prostate-specific antigen kinetics in

Full access

George Rodrigues, Himu Lukka, Padraig Warde, Michael Brundage, Luis Souhami, Juanita Crook, Fabio Cury, Charles Catton, Gary Mok, Andre-Guy Martin, Eric Vigneault, Jim Morris, Andrew Warner, Sandra Gonzalez Maldonado, Tom Pickles, and the Genitourinary Radiation Oncologists of Canada (GUROC)

and Oncology . Int J Radiat Oncol Biol Phys 1998 ; 41 : 267 – 272 . 26. Thompson A Keyes M Pickles T . Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: can PSA kinetics distinguish PSA